Tubize-Fin (TUB) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.001x

Based on the latest financial reports, Tubize-Fin (TUB) has a cash flow conversion efficiency ratio of -0.001x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.41 Million ≈ $-2.81 Million USD) by net assets (€1.89 Billion ≈ $2.20 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Tubize-Fin - Cash Flow Conversion Efficiency Trend (2004–2025)

This chart illustrates how Tubize-Fin's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Tubize-Fin debt and liabilities for a breakdown of total debt and financial obligations.

Tubize-Fin Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Tubize-Fin ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
News Corp A
NASDAQ:NWSA
0.025x
Jinduicheng Molybdenum Co Ltd
SHG:601958
0.031x
Antero Midstream Partners LP
NYSE:AM
0.473x
Shanghai International Airport Co Ltd
SHG:600009
0.042x
Viavi Solutions Inc
NASDAQ:VIAV
0.051x
Beijing Kunlun Tech Co Ltd
SHE:300418
-0.010x
Gotion High tech Co Ltd
SHE:002074
0.004x
Smithfield Foods, Inc. Common Stock
NASDAQ:SFD
0.002x

Annual Cash Flow Conversion Efficiency for Tubize-Fin (2004–2025)

The table below shows the annual cash flow conversion efficiency of Tubize-Fin from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see TUB market cap overview.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 €1.89 Billion
≈ $2.20 Billion
€91.84 Million
≈ $107.37 Million
0.049x +4432.70%
2024-12-31 €1.84 Billion
≈ $2.15 Billion
€-2.07 Million
≈ $-2.42 Million
-0.001x +1.28%
2023-12-31 €1.80 Billion
≈ $2.10 Billion
€-2.05 Million
≈ $-2.39 Million
-0.001x -101.14%
2022-12-31 €1.75 Billion
≈ $2.05 Billion
€174.23 Million
≈ $203.69 Million
0.099x +27868.38%
2021-12-31 €3.25 Billion
≈ $3.80 Billion
€-1.16 Million
≈ $-1.36 Million
0.000x +52.23%
2020-12-31 €2.79 Billion
≈ $3.27 Billion
€-2.09 Million
≈ $-2.45 Million
-0.001x -74.16%
2019-12-31 €2.66 Billion
≈ $3.11 Billion
€-1.15 Million
≈ $-1.34 Million
0.000x -101.33%
2018-12-31 €2.34 Billion
≈ $2.74 Billion
€75.76 Million
≈ $88.57 Million
0.032x -6.11%
2017-12-31 €2.12 Billion
≈ $2.47 Billion
€72.96 Million
≈ $85.30 Million
0.034x -0.28%
2016-12-31 €1.96 Billion
≈ $2.29 Billion
€67.70 Million
≈ $79.15 Million
0.035x +6.14%
2015-12-31 €1.95 Billion
≈ $2.28 Billion
€63.45 Million
≈ $74.18 Million
0.033x +8720.77%
2014-12-31 €1.62 Billion
≈ $1.90 Billion
€-613.00K
≈ $-716.66K
0.000x +28.75%
2013-12-31 €1.55 Billion
≈ $1.81 Billion
€-823.00K
≈ $-962.17K
-0.001x +43.61%
2012-12-31 €1.49 Billion
≈ $1.74 Billion
€-1.40 Million
≈ $-1.64 Million
-0.001x -1274.66%
2011-12-31 €1.55 Billion
≈ $1.81 Billion
€124.00K
≈ $144.97K
0.000x +110.32%
2010-12-31 €1.44 Billion
≈ $1.69 Billion
€-1.12 Million
≈ $-1.31 Million
-0.001x +91.77%
2009-12-31 €1.36 Billion
≈ $1.59 Billion
€-12.79 Million
≈ $-14.96 Million
-0.009x -311.75%
2008-12-31 €1.20 Billion
≈ $1.40 Billion
€5.32 Million
≈ $6.22 Million
0.004x +0.18%
2007-12-31 €1.26 Billion
≈ $1.47 Billion
€5.61 Million
≈ $6.55 Million
0.004x -98.16%
2006-12-31 €1.36 Billion
≈ $1.58 Billion
€327.96 Million
≈ $383.42 Million
0.242x +1799.40%
2005-12-31 €901.39 Million
≈ $1.05 Billion
€-12.84 Million
≈ $-15.01 Million
-0.014x -376.61%
2004-12-31 €592.56 Million
≈ $692.76 Million
€3.05 Million
≈ $3.57 Million
0.005x --

About Tubize-Fin

BR:TUB Belgium Biotechnology
Market Cap
$10.43 Billion
€8.92 Billion EUR
Market Cap Rank
#2278 Global
#8 in Belgium
Share Price
€200.40
Change (1 day)
+0.10%
52-Week Range
€121.40 - €247.50
All Time High
€247.50
About

Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. It engages in discovering and developing treatments for patients suffering from serious illnesses that affect the immune system or the central nervous system. The company was incorporated in 1928 and is based in Brussels, Belgium.